Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 6
1970 4
1971 6
1972 8
1973 8
1974 11
1975 5
1976 4
1977 6
1978 4
1979 5
1980 2
1981 4
1982 3
1983 2
1984 1
1985 4
1986 2
1987 2
1988 4
1989 4
1990 7
1991 7
1992 10
1993 6
1994 8
1995 6
1996 4
1997 9
1998 12
1999 16
2000 10
2001 16
2002 17
2003 13
2004 29
2005 14
2006 15
2007 22
2008 17
2009 20
2010 27
2011 31
2012 22
2013 21
2014 28
2015 29
2016 23
2017 33
2018 40
2019 35
2020 24
2021 29
2022 37
2023 21

Text availability

Article attribute

Article type

Publication date

Search Results

685 results

Results by year

Filters applied: . Clear all
Page 1
Genomic and phenotypic heterogeneity in prostate cancer.
Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Haffner MC, et al. Among authors: de marzo am. Nat Rev Urol. 2021 Feb;18(2):79-92. doi: 10.1038/s41585-020-00400-w. Epub 2020 Dec 16. Nat Rev Urol. 2021. PMID: 33328650 Free PMC article. Review.
Cancer overdiagnosis: a biological challenge and clinical dilemma.
Srivastava S, Koay EJ, Borowsky AD, De Marzo AM, Ghosh S, Wagner PD, Kramer BS. Srivastava S, et al. Among authors: de marzo am. Nat Rev Cancer. 2019 Jun;19(6):349-358. doi: 10.1038/s41568-019-0142-8. Nat Rev Cancer. 2019. PMID: 31024081 Free PMC article. Review.
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Guccini I, Revandkar A, D'Ambrosio M, Colucci M, Pasquini E, Mosole S, Troiani M, Brina D, Sheibani-Tezerji R, Elia AR, Rinaldi A, Pernigoni N, Rüschoff JH, Dettwiler S, De Marzo AM, Antonarakis ES, Borrelli C, Moor AE, Garcia-Escudero R, Alajati A, Attanasio G, Losa M, Moch H, Wild P, Egger G, Alimonti A. Guccini I, et al. Among authors: de marzo am. Cancer Cell. 2021 Jan 11;39(1):68-82.e9. doi: 10.1016/j.ccell.2020.10.012. Epub 2020 Nov 12. Cancer Cell. 2021. PMID: 33186519 Free article.
Prostate carcinogenesis: inflammatory storms.
de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, Gil J, Drake CG, Alimonti A. de Bono JS, et al. Among authors: de marzo am. Nat Rev Cancer. 2020 Aug;20(8):455-469. doi: 10.1038/s41568-020-0267-9. Epub 2020 Jun 16. Nat Rev Cancer. 2020. PMID: 32546840 Review.
SOX2 mediates metabolic reprogramming of prostate cancer cells.
de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EA, De Marzo AM, Mu P, Coloff JL, Szmulewitz RZ, Vander Griend DJ. de Wet L, et al. Among authors: de marzo am. Oncogene. 2022 Feb;41(8):1190-1202. doi: 10.1038/s41388-021-02157-x. Epub 2022 Jan 24. Oncogene. 2022. PMID: 35067686 Free PMC article.
Clinical implications of PTEN loss in prostate cancer.
Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Jamaspishvili T, et al. Among authors: de marzo am. Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Nat Rev Urol. 2018. PMID: 29460925 Free PMC article. Review.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. Among authors: de marzo am. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, Ji H, Allaf ME, Chapman C, Moore PA, Chen F, Sorg K, White AM, Church SE, Hudson B, Fields PA, Hu S, Denmeade SR, Pienta KJ, Pavlovich CP, Ross AE, Drake CG, Pardoll DM, Antonarakis ES. Shenderov E, et al. Among authors: de marzo am. Nat Med. 2023 Apr;29(4):888-897. doi: 10.1038/s41591-023-02284-w. Epub 2023 Apr 3. Nat Med. 2023. PMID: 37012549 Clinical Trial.
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.
Berry S, Giraldo NA, Green BF, Cottrell TR, Stein JE, Engle EL, Xu H, Ogurtsova A, Roberts C, Wang D, Nguyen P, Zhu Q, Soto-Diaz S, Loyola J, Sander IB, Wong PF, Jessel S, Doyle J, Signer D, Wilton R, Roskes JS, Eminizer M, Park S, Sunshine JC, Jaffee EM, Baras A, De Marzo AM, Topalian SL, Kluger H, Cope L, Lipson EJ, Danilova L, Anders RA, Rimm DL, Pardoll DM, Szalay AS, Taube JM. Berry S, et al. Among authors: de marzo am. Science. 2021 Jun 11;372(6547):eaba2609. doi: 10.1126/science.aba2609. Science. 2021. PMID: 34112666 Free PMC article.
685 results